• Home
  • About us
  • Partners
  • News
  • NEWS
  • Contact us
www.amlvaccin.eu
  • Home
  • About us
  • Partners
  • News
  • NEWS
  • Contact us

AML-VACCiN promoted by the European Commission

  • Home
  • /Geen categorie
  • /AML-VACCiN promoted by the European Commission

On February 28 2020 Jean-Eric Paquet (Director-General of the Research and Innovation department) wrote the following on Twitter:

”Rare diseases are a priority area of research funding for the EU. This is why we will continue to invest in R&I through #HorizonEU to further increase the concrete impact on #rarediseases.”

Together with this post he attached the Factsheet: Showcasing development of therapies for rare diseases. The AML-VACCiN project has been highlight on page 1.

You’ll find the factsheet by clicking on this link: Promotion AML-VACCiN by the EU

  • 03 March 2020
  • amlvaccin
  • Geen categorie
  •  Like

Share This

← Want to read more about the role of relapse vaccines in AML? Please read the article on this topic published in the November-December 2019 edition of MedNous
  • Categories

    • Article
    • Geen categorie
    • News
  • Recent Posts

    • AML-VACCiN promoted by the European Commission
    • Want to read more about the role of relapse vaccines in AML? Please read the article on this topic published in the November-December 2019 edition of MedNous
    • Third AML-VACCiN Consortium Meeting
    • Presentations of the preclinical results at the annual CCBIO Symposium
    • Presentation of the preclinical data at the annual CIMT meeting
  • PROJECT INFO

    This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667713. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.